Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Children's Oncology Group
Children's Oncology Group
GlaxoSmithKline
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
New Approaches to Neuroblastoma Therapy Consortium
M.D. Anderson Cancer Center
New Approaches to Neuroblastoma Therapy Consortium
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Children's Oncology Group
University of Virginia
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Bayer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Y-mAbs Therapeutics
Children's Oncology Group
Children's Hospital Los Angeles
Bristol-Myers Squibb
University of Iowa
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
New Approaches to Neuroblastoma Therapy Consortium
Children's Oncology Group
Children's Oncology Group
Nova Laboratories Limited
University of Iowa
Cancer Research UK